30.01.2024 15:40:28
|
Personalis, ClearNote Health Join Hands To Advance Epigenomic Technology
(RTTNews) - Personalis, Inc. (PSNL), a cancer genomics company on Tuesday said it entered into an agreement with ClearNote Health, Inc., a cancer detection company, to expand the epigenomic 5- hydroxymethylcytosine or 5hmC platform.
The company stated that the technology would accelerate the development of personalized cancer therapies as it tracks changes in 5hmC levels with the help of AI-based analytical methods, which would detect cancer earlier.
Currently, Personalis' stock is trading at $1.49, down 2.61 percent on the Nasdaq.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Personalis Inc Registered Shsmehr Nachrichten
05.11.24 |
Ausblick: Personalis zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Personalis Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Personalis Inc Registered Shs | 4,66 | -1,94% |
|